PSMA PET/CT 在新诊断不利中危前列腺癌男性中的诊断价值
回顾性纳入 396 例新诊断不利中危前列腺癌、以 PSMA PET/CT 作为初始分期手段的男性,37 例(9.3%)发现转移性疾病,其中分子影像局部区域淋巴结转移(miN1)29 例(7.3%)、远处转移(miM1)16 例(4.0%)。MRI 放射学肿瘤分期至少 T3(OR 2.72,95%CI 1.27-5.83,P=0.01)和阳性前列腺活检比例超过 50%(OR 3.87,95%CI 1.74-8.62,P=0.001)与 PSMA PET/CT 上的转移性疾病独立相关。
要点
- 396 例新诊断不利中危前列腺癌中 37 例(9.3%)PSMA PET/CT 发现转移。
- miN1 29 例(7.3%),miM1 16 例(4.0%)。
- MRI 分期至少 T3 与转移独立相关(OR 2.72,P=0.01)。
核心结论
- 新诊断不利中危前列腺癌男性中近十分之一观察到转移性疾病,PSMA PET/CT 在该人群中被认为具有诊断价值。
- 使用放射学肿瘤分期和阳性前列腺活检比例进一步分层,可能有助于识别 PSMA PET/CT 上有转移性疾病风险的患者。
研究设计与样本
- 回顾性研究新诊断不利中危前列腺癌、以 PSMA PET/CT 作为初始分期手段的男性患者。
- PSMA PET/CT 在多个诊断中心完成,由 2 个高容量前列腺癌中心内的专家核医学医师报告。
- 采用多变量 logistic 回归分析临床、生化、病理和放射学变量,以识别 PSMA PET/CT 上转移性疾病的潜在独立预测因素。
主要发现
- 共纳入 396 例新诊断不利中危前列腺癌男性。
- 37 例(9.3%)观察到转移性疾病,其中 29 例(7.3%)有分子影像局部区域淋巴结转移(miN1)。
- 16 例(4.0%)有远处转移(miM1)。
- MRI 上放射学肿瘤分期至少 T3 与 PSMA PET/CT 转移性疾病独立相关(OR 2.72,95%CI 1.27-5.83,P=0.01)。
- 阳性前列腺活检比例超过 50% 与 PSMA PET/CT 转移性疾病独立相关(OR 3.87,95%CI 1.74-8.62,P=0.001)。
关键数值与推荐
- MRI 放射学肿瘤分期至少 T3:OR 2.72(95%CI 1.27-5.83),P=0.01。
- 阳性前列腺活检比例超过 50%:OR 3.87(95%CI 1.74-8.62),P=0.001。
临床怎么用
- 作者认为 PSMA PET/CT 在新诊断不利中危前列腺癌人群中具有诊断价值。
- 作者认为使用放射学肿瘤分期和阳性前列腺活检比例进一步分层,可能有助于识别 PSMA PET/CT 上有转移性疾病风险的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our objective was to determine the diagnostic value of prostate-specific membrane antigen (PSMA) PET/CT in staging men with newly diagnosed unfavorable intermediate-risk prostate cancer (PCa). Methods: Patients with newly diagnosed unfavorable intermediate-risk PCa, in whom PSMA PET/CT was performed as a primary staging modality, were retrospectively studied. PSMA PET/CT was performed at several diagnostic centers and reported by expert nuclear medicine physicians within 2 high-volume PCa centers. A multivariate logistic regression analysis, taking into account clinical, biochemical, pathologic, and radiologic variables, was performed to identify potential independent predictors for metastatic disease on PSMA PET/CT. Results: In total, 396 men with newly diagnosed unfavorable intermediate-risk PCa were studied. Metastatic disease was observed in 37 (9.3%) men, of whom 29 (7.3%) had molecular imaging locoregional lymph node metastases (miN1) and 16 (4.0%) had distant metastases (miM1). A radiologic tumor stage of at least T3 on MRI (odds ratio, 2.72 [95% CI, 1.27-5.83]; P = 0.01) and more than 50% positive prostate biopsies (odds ratio, 3.87 [95% CI, 1.74-8.62]; P = 0.001) were found to be independently associated with metastatic disease on PSMA PET/CT. Conclusion: Given that metastatic disease was observed in nearly 1 in 10 men with newly diagnosed unfavorable intermediate-risk PCa, PSMA PET/CT is considered to be of diagnostic value within this population. Further stratification using the radiologic tumor stage and the percentage of positive prostate biopsies could aid in identifying those patients at risk of having metastatic disease on PSMA PET/CT.
引用
- Hagens MJ, Luining WI, Jager A, et al. The Diagnostic Value of PSMA PET/CT in Men with Newly Diagnosed Unfavorable Intermediate-Risk Prostate Cancer. J Nucl Med. 2023. PMID: 37385673. doi:10.2967/jnumed.122.265205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。